BIOMAT Database Logo BIOMAT Database Logo

Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas. 1998

J P Stevenson, and R M Scher, and R Kosierowski, and S C Fox, and M Simmonds, and K S Yao, and F Green, and C Broom, and S Z Fields, and J B Krebs, and P J O'Dwyer
Thomas Jefferson University, Kimmel Cancer Center, Philadelphia, PA 19107, USA.

The aim of this study was to determine the efficacy and toxicity of topotecan administered as a 21-day continuous intravenous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas. 26 previously untreated patients with advanced or metastatic pancreatic adenocarcinoma received topotecan at a dose of 0.5 mg/m2/day or 0.6 mg/m2/day as a continuous intravenous infusion for 21 days. Courses were repeated every 28 days. 26 patients were assessable for response and toxicity on an intent-to-treat basis. The initial 8 patients at a starting dose of 0.6 mg/m2/day experienced unacceptable myelosuppression and dose delays. The subsequent 18 patients, therefore began therapy at a dose of 0.5 mg/m2/day. The major toxicity of topotecan at this dose and schedule was myelosuppression, which was reversible and non-cumulative. There were no complete responses and two partial responses for a total response rate of 8% (95% confidence interval, 1-25%). Response durations were 17 and 45 weeks. Stable disease was seen in 3 patients. The median time to progression for all patients was 8 weeks and the median survival was 20 weeks. Topotecan given as a 21-day continuous intravenous infusion has a similar response rate and median survival to our previously reported study of the 5-day short infusion regimen in pancreatic carcinoma.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010190 Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). Cancer of Pancreas,Pancreatic Cancer,Cancer of the Pancreas,Neoplasms, Pancreatic,Pancreas Cancer,Pancreas Neoplasms,Pancreatic Acinar Carcinoma,Pancreatic Carcinoma,Acinar Carcinoma, Pancreatic,Acinar Carcinomas, Pancreatic,Cancer, Pancreas,Cancer, Pancreatic,Cancers, Pancreas,Cancers, Pancreatic,Carcinoma, Pancreatic,Carcinoma, Pancreatic Acinar,Carcinomas, Pancreatic,Carcinomas, Pancreatic Acinar,Neoplasm, Pancreas,Neoplasm, Pancreatic,Neoplasms, Pancreas,Pancreas Cancers,Pancreas Neoplasm,Pancreatic Acinar Carcinomas,Pancreatic Cancers,Pancreatic Carcinomas,Pancreatic Neoplasm
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006402 Hematologic Diseases Disorders of the blood and blood forming tissues. Blood Diseases,Hematological Diseases,Blood Disease,Disease, Blood,Disease, Hematologic,Disease, Hematological,Diseases, Blood,Diseases, Hematologic,Diseases, Hematological,Hematologic Disease,Hematological Disease
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

J P Stevenson, and R M Scher, and R Kosierowski, and S C Fox, and M Simmonds, and K S Yao, and F Green, and C Broom, and S Z Fields, and J B Krebs, and P J O'Dwyer
Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas.
January 1996, Investigational new drugs,
J P Stevenson, and R M Scher, and R Kosierowski, and S C Fox, and M Simmonds, and K S Yao, and F Green, and C Broom, and S Z Fields, and J B Krebs, and P J O'Dwyer
Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer.
September 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
J P Stevenson, and R M Scher, and R Kosierowski, and S C Fox, and M Simmonds, and K S Yao, and F Green, and C Broom, and S Z Fields, and J B Krebs, and P J O'Dwyer
Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small-cell lung cancer.
October 1998, American journal of clinical oncology,
J P Stevenson, and R M Scher, and R Kosierowski, and S C Fox, and M Simmonds, and K S Yao, and F Green, and C Broom, and S Z Fields, and J B Krebs, and P J O'Dwyer
Phase II study of a 21-day continuous infusion schedule with epirubicin in metastatic colorectal cancer.
April 1988, European journal of cancer & clinical oncology,
J P Stevenson, and R M Scher, and R Kosierowski, and S C Fox, and M Simmonds, and K S Yao, and F Green, and C Broom, and S Z Fields, and J B Krebs, and P J O'Dwyer
Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer.
April 2001, British journal of cancer,
J P Stevenson, and R M Scher, and R Kosierowski, and S C Fox, and M Simmonds, and K S Yao, and F Green, and C Broom, and S Z Fields, and J B Krebs, and P J O'Dwyer
Topotecan as a 21-day continuous infusion with accelerated 3D-conformal radiation therapy for patients with glioblastoma.
January 1999, Frontiers of radiation therapy and oncology,
J P Stevenson, and R M Scher, and R Kosierowski, and S C Fox, and M Simmonds, and K S Yao, and F Green, and C Broom, and S Z Fields, and J B Krebs, and P J O'Dwyer
A phase II study of a 21 day continuous infusion schedule with epirubicin in advanced gastric cancer.
October 1989, European journal of cancer & clinical oncology,
J P Stevenson, and R M Scher, and R Kosierowski, and S C Fox, and M Simmonds, and K S Yao, and F Green, and C Broom, and S Z Fields, and J B Krebs, and P J O'Dwyer
Cellular and clinical pharmacokinetic/pharmacodynamic basis for lack of efficacy of 21-day continuous topotecan in patients with untreated advanced adenocarcinoma of the pancreas.
January 2000, Tumori,
J P Stevenson, and R M Scher, and R Kosierowski, and S C Fox, and M Simmonds, and K S Yao, and F Green, and C Broom, and S Z Fields, and J B Krebs, and P J O'Dwyer
Multicenter phase II trial with 5-day continuous infusion of vindesine in metastatic malignant melanoma.
September 1984, Cancer treatment reports,
J P Stevenson, and R M Scher, and R Kosierowski, and S C Fox, and M Simmonds, and K S Yao, and F Green, and C Broom, and S Z Fields, and J B Krebs, and P J O'Dwyer
Phase II trial of topotecan by continuous infusion in patients with advanced soft tissue sarcomas, a SWOG study. Southwest Oncology Group.
February 2002, Investigational new drugs,
Copied contents to your clipboard!